EverZinc Invests in Zano®
4.12.2018 16:30:00 EET | Business Wire | Press release
EverZinc, the leading global provider of specialty zinc materials, today announced an investment of more than 5 Million Euros in order to increase the production capacity of the Zano® (ultra-fine zinc oxide) product line. Production capacity of EverZinc has been increased by 30% in 2018 and will increase further by another 30% in 2019. EverZinc is also investing in an additional Zano® production line, which is scheduled to be operational from Q1 2020 onwards. This new line will expand EverZinc’s current Zano capacity by another 50%. In total EverZinc is going to triple the production capacity of Zano® in this 48-month period.
The market for UV filters is envisaging major changes, and there is a growing demand for ultra-fine zinc oxide as a mineral UV filter (due to a higher public awareness for UV-A protection, an increasing worldwide interest for natural UV filters, the ban on the chemical filters oxybenzone and octinoxate in several island regions, and the ECHA official opinion about ultra-fine TiO2). “This worldwide trend which is accelerating quickly has resulted in an unforeseen expansion of the zinc oxide suncare market,” said Vincent Dujardin, EverZinc’s Chief Executive Officer. “EverZinc is dedicated to invest in new production capacity of Zano® to support the growth of the zinc-oxide-based sunscreen and skincare market because we believe in the superior characteristics of Zano®, combining broadband UVA/UVB protection and a high level of transparency. Besides, it offers a natural solution to replace chemical filters.”
Following this Capex expenditure, EverZinc is also raising Zano®’s price for material delivered from 1 January 2019 onwards. “Zano®’s price has been stable for many years despite severe cost increases related to energy inflation, zinc’s higher price, carbon emission rights, and staff costs,” concluded Dujardin.
About EverZinc
EverZinc, an OpenGate Capital portfolio company, is committed to creating products that matter. The company is a global provider of specialty zinc materials, including fine zinc powders; zinc oxides; battery zinc powders; and Zano®, an ultra-fine zinc oxide. EverZinc products are used in a wide variety of applications, including corrosion inhibiting paints, performance tires, pharmaceuticals, ceramics, glass, sunscreen, alkaline batteries, and other products. With manufacturing operations located in Belgium, the Netherlands, Norway, China, and Malaysia, EverZinc processes more than 180,000 tons of materials of which 40% are recycled and refined at eight production sites to serve its growing global customer base. Learn more at www.everzinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005362/en/
Contact information
Media contact
Grégory Sacré
gregory.sacre@everzinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 19:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulatory compliance on behalf of developers, removing a significant operational and legal barrier for studios looking to distribute through alternat
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 19:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security that enterprises require. Through this collaboration, these signals can be serve
Boomi and Guru Partner to Deliver AI-Powered Enterprise Knowledge Enriched by Real-Time Data Activation14.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Guru, the AI-powered enterprise knowledge platform, today announced a technology partnership to help organizations unlock the full value of their enterprise data for AI-driven decision-making. Unveiled at Boomi World 2026, the partnership makes Guru a launch partner for Boomi Connect, Boomi’s new managed connector service, and integrates Guru’s knowledge agents with Agentstudio and the Boomi MCP Registry to deliver richer, more accurate, and more actionable insights to knowledge workers and AI agents alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514440755/en/ Guru was selected as a Boomi Connect launch partner because its AI-powered knowledge platform represents one of the highest-value consumption patterns for managed enterprise connectivity. Knowledge agents are only as effective as the data they can access, and Guru’s ability to synthesize insights across enterpris
IQM and Real Asset Acquisition Corp. Announce Public Filing of Form F-4 Registration Statement with the SEC14.5.2026 16:55:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today the public filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in connection with the proposed Business Combination Agreement announced February 23, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514989293/en/ IQM Radiance quantum computer Jan Goetz, Chief Executive Officer and Co-Founder, IQM, said: “This filing is a milestone we have worked hard to reach, and it signals our readiness to operate at a new level. Public markets will give IQM the platform and capital to accelerate everything we are building as we work towards delivering fault-toleranc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
